Gene therapy Progress and Prospects: Gene therapy for the hemophilias
暂无分享,去创建一个
[1] T. VandenDriessche,et al. Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice. , 2000, Human gene therapy.
[2] C. Slaughter,et al. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. , 2002, Blood.
[3] M. Kay,et al. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system , 2000, Nature Genetics.
[4] R. Samulski,et al. AAV vectors: is clinical success on the horizon? , 2000, Gene Therapy.
[5] Alan McClelland,et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. , 2003, Blood.
[6] Alan McClelland,et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.
[7] M. Garcia-Blanco,et al. Messenger RNA repair and restoration of protein function by spliceosome-mediated RNA trans-splicing. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[8] I. Verma,et al. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] M. Poon. Use of recombinant factor VIIa in hereditary bleeding disorders , 2001, Current opinion in hematology.
[10] R. Herzog,et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. , 2002, Blood.
[11] R. Samulski,et al. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[12] A. Sharpe,et al. Prevention and treatment of factor VIII inhibitors in murine hemophilia AJ. Qian, M. Collins, A.H. Sharpe, et al. Blood 95:1324–1329, 2000 , 2000 .
[13] B. Brown,et al. Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy. , 2002, Blood.
[14] D. Treco,et al. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. , 2001, The New England journal of medicine.
[15] Lili Wang,et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[16] R. Samulski,et al. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[17] D. Lillicrap. Hemophilia treatment. Gene therapy, factor VIII antibodies and immune tolerance: hopes and concerns. , 2000, Haematologica.
[18] C. Walsh,et al. Induction of tolerance to human factor VIII in mice. , 2001, Blood.
[19] M. Kay,et al. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. , 2000, Blood.
[20] Liming Chang,et al. Use of blood outgrowth endothelial cells for gene therapy for hemophilia A. , 2002, Blood.
[21] K. Kurachi,et al. Bone marrow stromal cells as a genetic platformfor systemic delivery of therapeutic proteins in vivo: human factor IX model , 2003, The journal of gene medicine.